March 2, 2023 05:00 AM ESTUpdated 06:13 AM

Eli Lilly licenses early-stage non-opioid pain drug from Belgian biotech Confo

Lei Lei Wu

News Reporter

Eli Lilly has licensed a Phase I non-opioid pain candidate from Confo Therapeutics, adding to the handful of pain drugs the pharma company is trying …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly licenses early-stage non-opioid pain drug from Belgian biotech Confo

Lei Lei Wu

News Reporter

Sign up to read this article for free.

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Eli Lil­ly li­cens­es ear­ly-stage non-opi­oid pain drug from Bel­gian biotech Con­fo

Lei Lei Wu

News Reporter

Sign up to read this article for free.

more like this

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Eli Lilly licenses early-stage non-opioid pain drug from Belgian biotech Confo

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials